Biohit measures acetaldehyde levels in Finnish sour whole

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Biohit measures acetaldehyde levels in Finnish sour whole milk ("viili") products - yogurts contain significantly higher levels of carcinogenic acetaldehyde

Biohit Oyj September 20, 2013 at 15:00. local time (EET)

Finnish healthcare company Biohit Oyj has measured the concentrations of acetaldehyde in Finnish sour whole milk (‘viili’) products. Acetaldehyde is a substance which has an apple flavor, and it is especially rich in foods prepared with a fermentation process such as alcoholic beverages, vinegars and dairy products. The International Agency for Research on Cancer (IARC), a part of the World Health Organization, has classified acetaldehyde as a Group I human carcinogen. Therefore, acetaldehyde is equally dangerous cancer agent such as asbestos, formaldehyde and benzene. 

Biohit measured the concentrations of carcinogenic acetaldehyde in viili products generally on sale in Finland. The sample consisted of 21 different brands selected randomly from grocery outlets in the Greater Helsinki Region. 

The analysis demonstrated that the concentrations of carcinogenic acetaldehyde in viili products varied between 0-12 µM. Eleven brands contained no concentrations of carcinogenic acetaldehyde. The highest concentration measured was 12 µM. 

In previous studies on yogurts, the concentrations of carcinogenic acetaldehyde varied between 14-394 µM. Only in one yogurt brand the concentration of carcinogenic acetaldehyde was under the threshold level (100 µM or possibly significantly less). In all other brands, the concentration was equal to or greater than 205 µM. Thus, the measured yogurts contained on the average 20 times higher levels of carcinogens than viili products. 

“Finnish consumers should have the right to know that the food they eat is safe and avoid accumulation of acetaldehyde. Unfortunately, information on acetaldehyde is not included on labels,” says Semi Korpela, CEO, Biohit. “Consumers should be entitled to have information that is vital to their wellbeing in the long run – especially as Finnish food is considered to be among the safest in the world.”

The measurement results and additional information:  www.biohithealthcare.com/laboratory-services/determination-of-acetaldehyde http://www.acetium.com/node/6   - test your acetaldehyde exposure 

Additional information:

CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit's series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 11

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 7

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 7

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 11

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 4

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 10

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 6

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 10

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 5

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

Chart Industries Transitions to New Leadership in Upcoming Merger

Updated Category News Views 231

Chart Industries Announces Leadership Change Chart Industries (NYSE: GTLS) is taking significant steps toward a future transition as CEO Jill Evanko has announced plans to assume a senior advisor role starting in early 2026. This change comes as she prepares to take on a new executive opportunity within a privately owned company. Evanko has been essential in steering the...

Continue Reading
Understanding Debtors: Insights into Realkredit Danmark A/S

Updated Category News Views 299

Understanding Debtors: Key Insights from Realkredit Danmark A/S At the heart of any effective financial institution is a reliable understanding of its debtors. Realkredit Danmark A/S, a prestigious name in the financial landscape, recently made available a detailed breakdown of its debtors. This information is crucial for various stakeholders, including investors,...

Continue Reading
Cryptocurrency Market Update: Bitcoin Droops under $59K with ETF Inflows Soaring

Updated Category News Views 148

Bitcoin's Recent Performance The cryptocurrency market has been lively lately, especially with Bitcoin recently falling below the $59,000 threshold. Investors had been optimistic, especially since the cryptocurrency saw a remarkable $436 million in net ETF inflows just last week. This significant influx signals that institutional interest in cryptocurrencies is still...

Continue Reading
Enhancing Specialized Care for ARFID Treatment with Emily Program

Updated Category News Views 169

Introduction to The Emily Program and ARFID The Emily Program is making significant strides in specialized care for individuals with Avoidant/Restrictive Food Intake Disorder (ARFID). This condition, often misunderstood, has recently begun to garner more attention from healthcare experts. In response to this need, The Emily Program is offering advanced treatment...

Continue Reading
Investigation of Alleged Securities Fraud at 3D Systems Unfolds

Updated Category News Views 167

Overview of Legal Actions Against 3D Systems Corporation Recently, investors in 3D Systems Corporation have found themselves entangled in a potential securities fraud lawsuit. This case serves as a cautionary tale, highlighting the importance of transparency and integrity in corporate communication. The allegations stem from assertions that the company made misleading...

Continue Reading